Results 271 to 280 of about 156,081 (291)
The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions. [PDF]
Xue Z+21 more
europepmc +1 more source
Dopamine Receptor 1 Treatment Promotes Epithelial Repair of Corneal Injury by Inhibiting NOD-Like Receptor Protein 3-Associated Inflammation. [PDF]
Li L, Yu Y, Zhuang Z, Wu Q, Lin S, Hu J.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-vornhagen+2 more
exaly
Current treatment and recent progress in gastric cancer
Ca-A Cancer Journal for Clinicians, 2021Smita S Joshi, Brian D Badgwell
exaly
A review of cancer immunotherapy toxicity
Ca-A Cancer Journal for Clinicians, 2020Lucy Boyce Kennedy
exaly
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Ca-A Cancer Journal for Clinicians, 2020Vaibhav G Patel+2 more
exaly
Evolving standards of care and new challenges in the management of HER2‐positive breast cancer
Ca-A Cancer Journal for Clinicians, 2020Ciara C O’sullivan+2 more
exaly